EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

High-Voltage Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation

Vivek Y Reddy, Jan Petru, Johan Vijgen, Mohit Turagam, Jacob S Koruth, Moritoshi Funasako, Pavel Hala, Pieter Koopman, Jan Skoda, Giuseppe Stifano, Mirco Vincenzo La Fazia, David Kenigsberg und 2 weitere

JACC: Clinical Electrophysiology · 2026-10 · 12 (10) · 2370-2384

DOI: 10.1016/j.jacep.2026.04.012 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026-10. Verfasst von Vivek Y Reddy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, 1st Faculty of Medicine, Charles University and Faculty Hospitals Motol and Homolka, Prague, Czech Republic; Helmsley Elect…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Irreversible Electroporation Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Most pulsed field ablation (PFA) technologies for atrial fibrillation use microsecond-scale pulses. Nanosecond pulses, by virtue of their short duration, enable larger pulse amplitudes to project lesion depth, without near-field thermal effects. OBJECTIVES: The goal of this study was to determine the outcomes of treating paroxysmal atrial fibrillation using a novel circular nanosecond PFA (nsPFA) catheter. METHODS: In a first-in-human study of patients with symptomatic paroxysmal atrial fibrillation, the nsPFA catheter was used to deliver 2.5-second or 5-second applications. Invasive remapping assessed lesion durability at 2 to 3 months, with additional nsPFA for incomplete lesions. Follow-up included transtelephonic monitoring and Holter monitoring at 6 and 12 months. RESULTS: At 3 centers, 177 patients (mean age 61 ± 10 years; 36% female; left atrial diameter 41 ± 5 mm) underwent pulmonary vein isolation (PVI) using 2.5-second (n = 36 patients) or 5-second (n = 141) applications. Additional ablation was at the posterior wall (n = 87), cavotricuspid isthmus (n = 11), or mitral isthmus (n = 29). All (100%) lesions were acutely successful, with transpired PVI time of 12 ± 5 minutes, and total left atrial dwell time for the nsPFA catheter of 19 ± 13 minutes. Total procedure and fluoroscopy times were 61 ± 27 minutes and 9 ± 6 minutes, respectively. Three (of 177 [1.7%]) primary serious adverse events occurred: inflammatory pericardial effusion, hemolysis with acute kidney injury, and stroke. Post procedure brain magnetic resonance imaging (35 patients) revealed 11.4% silent cerebral events (DWI+ / ADC-reduced) and 11.4% silent cerebral lesions (SCE plus FLAIR+). PVI durability with the 5-second applications was 91%. The 1-year estimate for freedom from atrial arrhythmia was 89.7% (95% CI: 80.5%-94.6%). CONCLUSIONS: nsPFA demonstrated reasonable safety, good lesion durability, and favorable 1-year clinical effectiveness. (Evaluation of the CellFX® Nano-Pulsed Field Ablation [PFA] 360 Catheter Endocardial Ablation System for the Treatment of Atrial Fibrillation; NCT06696170).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationIrreversible Electroporation TherapyAgedFemaleHumansMaleMiddle AgedPulmonary VeinsTreatment Outcome

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationnanosecondpulmonary vein isolationpulsed field ablation

Autor:innen und Institutionen

  • Department of Cardiology, 1st Faculty of Medicine, Charles University and Faculty Hospitals Motol and Homolka, Prague, Czech Republic; Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, New…
  • Department of Cardiology, 1st Faculty of Medicine, Charles University and Faculty Hospitals Motol and Homolka, Prague, Czech Republic.
  • Jessa Ziekenhuis, Hasselt, Belgium.
  • Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, New York, USA.
  • Division of Cardiology, University of Tor Vergata, Rome, Italy.
  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.

Zitieren

APA

Reddy, V. Y., Petru, J., Vijgen, J., Turagam, M., Koruth, J. S., Funasako, M., Hala, P., Koopman, P., Skoda, J., Stifano, G., La Fazia, M. V., Kenigsberg, D., Natale, A., & Neuzil, P. (2026). High-Voltage Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation. JACC: Clinical Electrophysiology, 12(10), 2370-2384. https://doi.org/10.1016/j.jacep.2026.04.012

Vancouver

Reddy VY, Petru J, Vijgen J, Turagam M, Koruth JS, Funasako M, et al. High-Voltage Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation. JACC: Clinical Electrophysiology. 2026;12(10):2370-2384. doi:10.1016/j.jacep.2026.04.012

BibTeX
@article{Reddy2026,
  author = {Reddy, Vivek Y and Petru, Jan and Vijgen, Johan and Turagam, Mohit and Koruth, Jacob S and Funasako, Moritoshi and Hala, Pavel and Koopman, Pieter and Skoda, Jan and Stifano, Giuseppe and La Fazia, Mirco Vincenzo and Kenigsberg, David and Natale, Andrea and Neuzil, Petr},
  title = {High-Voltage Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  volume = {12},
  number = {10},
  pages = {2370--2384},
  doi = {10.1016/j.jacep.2026.04.012}
}
Kostenlos starten →